CAMBRIDGE, Mass., Dec. 4 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announces the acceptance of four abstracts for presentation at the American Society for Clinical Pharmacology and Therapeutics annual meeting to be held April 2-5, 2008. The Society is the largest scientific and professional organization serving the discipline of clinical pharmacology.
These abstracts address the basis for adverse event outcomes and other key findings in previous surgical studies of Hemopure. Biopure and the collaborating scientists also address the safety and efficacy of both Hemopure and Hemoglobin-based oxygen carriers (HBOCs) in general. The titles, authors and affiliations are as follows:
RISK OF ADVERSE OUTCOME DUE TO ACUTE ANEMIA IN THE ORTHOPEDIC SURGICAL SETTING. L. B. Pearce, A. N. Pitman; Biopure Corporation, Cambridge, MA.
BREAKING THE RULES: MISINTERPRETATION OF DOSE-RESPONSE RELATIONSHIPS IN CLINICAL TRIALS. L. B. Pearce, A. N. Pitman, A. G. Greenburg; Biopure Corporation, Cambridge, MA.
A FLEXIBLE OUTCOME SCORING SYSTEM FOR CLINICAL TRIALS. A. N. Pitman, L. B. Pearce; Biopure Corporation, Cambridge, MA.
APPLICATION OF A UNIQUE SCORING SYSTEM FOR NUMERICAL DETERMINATION OF A BENEFIT RISK RATIO IN CLINICAL TRIALS. L. B. Pearce(1), A. Pitman,(1) A. G. Greenburg,(1) D. A. Freilich,(2) L. Kaplan(3); (1)Biopure Corporation, Cambridge, MA, (2)Naval Medical Research Center, Silver Spring, MD, (3)Yale University School of Medicine, New Haven, CT.
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin
'/>"/>
| SOURCE Biopure Corporation Copyright©2007 PR Newswire. All rights reserved |